Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals
The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
Zoetis Inc's Q3 2024 results show a 16% EPS increase and an 11% revenue boost. The company raises its 2024 guidance, highlighting strong global growth in key segments.
FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic dermatitis. The drug, proven effective in studies, faces adoption challenges due to vaccination warnings and adverse event concerns.
